Patient group
Erwachsene mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD), die Anti-Aquaporin- 4-Immunglobulin-G(AQP4-IgG)-seropositiv sind
final resolution2023-01-19active
Arzneimittel-Richtlinie/Anlage XII: Inebilizumab (Neuromyelitis-optica-Spektrum-Erkrankungen, Anti-Aquaporin-4-IgG-seropositiv)
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Structured conclusion
Final result by patient group
1 source-verified result
Decision orientation
What the G-BA did
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2023-01-19
- Effective
- 19.01.2023
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package